Azzad Asset Management Inc. ADV Buys Shares of 1,004 Medpace Holdings, Inc. $MEDP

Azzad Asset Management Inc. ADV bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,004 shares of the company’s stock, valued at approximately $564,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of MEDP. NewEdge Advisors LLC increased its stake in Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC purchased a new stake in Medpace during the second quarter worth about $296,000. Finally, M&T Bank Corp increased its stake in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported a Q4 beat and raised FY‑2026 earnings guidance (EPS range 16.68–17.50), with revenue and margins improving year‑over‑year — a fundamental driver supporting the stock.
• Neutral Sentiment: Zacks published a comparison piece weighing PACS vs MEDP for value investors; these types of relative‑value writeups can attract attention but don’t directly change company fundamentals. PACS vs. MEDP: Which Stock Is the Better Value Option?
• Neutral Sentiment: Brokerage consensus on Medpace remains a “Hold” per recent aggregation — that suggests analysts are mixed despite solid results, so follow analyst note revisions for directional signals. Medpace Receives Consensus “Hold”
• Negative Sentiment: A wave of law firms has announced investigations and multiple class‑action notices alleging securities law violations tied to disclosures during an April 22, 2025–Feb 9, 2026 class period; several firms are soliciting lead plaintiffs — this increases legal and reputational risk and can pressure the stock. Medpace Shareholders — Contact Law Offices About Securities Fraud Investigation
• Negative Sentiment: An investor filed suit alleging that demand projections were misstated and tied the allegations to a roughly 16% stock decline — a concrete complaint that could lead to litigation costs or settlements if claims advance. Medpace Investor Sues Over Demand Projections

Medpace Stock Performance

MEDP stock opened at $520.65 on Thursday. The company’s 50 day moving average price is $476.51 and its 200 day moving average price is $537.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm has a market capitalization of $14.87 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 2.39 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period in the prior year, the firm earned $3.67 earnings per share. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of recent research reports. Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday, February 13th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a research note on Tuesday, February 10th. Finally, Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.